Day: November 16, 2019
– Clinical responses in seven out of 14 patients with synovial sarcoma by RECIST 1.1 –– Clinical benefit in 13 out of 14 patients –– One RECIST response maintained for more than 9 months after SPEAR T-cell infusion –PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 16, 2019 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated data from people with synovial sarcoma treated in the ongoing Phase 1 trial with ADP-A2M4. The oral presentation by Brian Van Tine, MD, PhD of Washington University School of Medicine in St. Louis, took place earlier today at the Connective Tissue Oncology Society (CTOS) annual meeting in Tokyo, Japan. Today’s presentation was an update of the data that Dr. Van Tine presented at ESMO on September 30.Out...
China Gold International Reports Change in Board Composition
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, Nov. 15, 2019 (GLOBE NEWSWIRE) — China Gold International Resources Corp. Ltd. (TSX: CGG; HKEx: 2099) (the “Company” or “China Gold International Resources”) announces that, effective immediately, its board of directors (the “Board”) has accepted the following change in the Board composition.The board of directors of the Company (the “Board”) hereby announces that Mr. SONG Xin (先生) has resigned as the Chairman and Executive Director of the Company with effect from November 14, 2019, Vancouver time. Mr. SONG tendered his resignation in order to assume and devote his time to his new position as Chairman of China Energy Conservation and Environmental Protection Group Co. Ltd.Mr. SONG has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to...